NCT01861912Unknown2 期
Arsenic Trioxide TACE and Intravenous Administration Compared With Arsenic Trioxide TACE Alone in Unresectable Hepatocellular Carcinoma: a Randomized, Parallel, Controlled, Multi-center Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 258
- 主要终点
- Time to Progression
研究概览
简要总结
The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Having signed informed consent;
- •Histological or clinical diagnosis of hepatocellular carcinoma（HCC）;
- •The target lesion should had at least one diameter line available for measurement, with the maximum diameter ≥5cm and ≤10cm；
- •Barcelona Clinic Liver Cancer staging B or C;
- •Child-Pugh liver function class: score≤7；
- •Eastern Cooperative Oncology Group performance 0 or 1;
- •At least 12 weeks life expectancy;
- •Never received systemic treatment, such as oral molecularly targeted drugs and systemic chemotherapy;
- •Be able to abide by the treatment and follow-up plan；
- •Adequate results for laboratory tests, including:
- •Neutrophil count≥1.5×109/L, platelet count≥60×109 /L; hemoglobin≥85g/L;
- •Total bilirubin≤51.3 μmol/L, albumin≥28 g/L,and alanine aminotransferase and aspartate aminotransferase≤5 times the upper limit of the normal range;
- •Amylase and lipase≤1.5 times the upper limit of the normal range
- •Serum creatinine≤20 g/L
- •Prothrombin time international normalized ratio ≤1.7; or prothrombin time≤4seconds above control;
- •Left ventricular ejection fraction≥50% according to two-dimensional echocardiography;
- •Contraception: during the trail and 12 weeks after the withdrawal, female of childbearing age (WOCBP), WOCBP whose male partners receive study drug or male must use appropriate contraceptive to avoid pregnancy;
排除标准
- •Disease should be excluded:
- •CT / MRI showed diffuse lesions;
- •Extrahepatic metastasis (metastasis in lungs not included);
- •Invasion in the main portal vein / vena cava or other major vascular;
- •Previous shunt surgery;
- •PreviousTACE or transarterial embolization for HCC, unless there is a untreated lesion;
- •Hepatic encephalopathy in the past or present;
- •Current ascites requiring treatment;
- •Medical history and concomitant diseases:
- •Previous or current cancer other than HCC, unless it is cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1). Cancer having received curative treatment 5 years ago will not be excluded;
- •Disease history in the cardiovascular system as the following:
- •(a)Uncontrolled hypertension；(b)Congestive heart failure in New York Heart Association grade 3 or 4; (c)Active coronary artery disease within 12 months, unstable angina or newly diagnosed angina/myocardial infarction;(d)Arrhythmia requiring drugs other than β-blockers and digoxin;(e)Valvular heart disease ≥ CTCAE grade 2； c) Corrected QT interval (Fridericia)> 450 ms confirmed by 2 ECGs in a row d) Thrombotic or embolic events within 6 months, e) Gastrointestinal bleeding within 6 months; f) Unstable and / or active stomach ulcer within 6 months, unless gastroscopy showed it to be fully recovered; g) Variceal bleeding within 6 months; h) Unhealed wound or ulcer, fracture within 3 months; i) Major surgery, open biopsy, or severe trauma within 3 weeks; j) History of organ transplant or subjects in the transplant waiting list; k) Uncontrolled abnormal thyroid function; l) HIV infection; m) Active or untreated hepatitis B;
- •laboratory tests unsuitable for the enrollment：
- •Hyponatremia, serum sodium <130 mmol / L；
- •Hypokalemia, serum potassium <3.5 mmol / L；
- •Allergic reactions to arsenic trioxide and any other drugs used in this trail;
- •Forbidden therapies and/or drugs:
- •Condensation treatment (e.g., warfarin or heparin);
- •Chronic antiplatelet therapy (Aspirin ≥ 300 mg / day; clopidogrel ≥ 75 mg / day);
- •Radiotherapy within 4 weeks;
研究组 & 干预措施
Arsenic trioxide TACE
Active Comparator
Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
干预措施: Arsenic trioxide TACE (Device)
Arsenic trioxide TACE
Active Comparator
Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
干预措施: lipiodol (Drug)
Arsenic trioxide TACE+IV
Experimental
- Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
- Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
干预措施: Arsenic trioxide TACE (Device)
Arsenic trioxide TACE+IV
Experimental
- Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
- Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
干预措施: Arsenic trioxide intravenous infusion (Drug)
Arsenic trioxide TACE+IV
Experimental
- Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
- Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
干预措施: lipiodol (Drug)
Arsenic trioxide TACE+IV
Experimental
- Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
- Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
干预措施: NaCl solution (Drug)
结局指标
主要结局
Time to Progression
时间窗: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.
Time to progression in our study is defined as the time from a patient's enrollment to the time for disease progression (according to Recist1.1).
次要结局
- Overall Survival(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.)
- Quality of Life(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.)
- Safety(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.)
研究者
Ligong Lu
MD
Guangdong Provincial People's Hospital
相似试验
已完成
1 期
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AMLMyelodysplastic SyndromeNCT00195104Weill Medical College of Cornell University87
尚未招募
4 期
Clinical efficacy of arsenic trioxide combined with carboplatin for neoadjuvant chemotherapy for locally advanced cervical cancerCervical cancerITMCTR1900002399The First Affiliated Hospital of Guangzhou University of Chinese Medicine
终止
2 期
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaLeukemiaMyelodysplastic SyndromesNCT00118196Medical University of South Carolina1
终止
2 期
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)Systemic LupusNCT01738360Nantes University Hospital11
终止
1 期
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesMyelodysplastic SyndromesLeukemiaNCT00234000Jonsson Comprehensive Cancer Center1